The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global CD62L Antibody Market 2025 by Company, Regions, Type and Application, Forecast to 2029

Global CD62L Antibody Market 2025 by Company, Regions, Type and Application, Forecast to 2029

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1774845

No of Pages : 124

Ask Your Query

Synopsis
The global CD62L Antibody market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells.

This report is a detailed and comprehensive analysis for global CD62L Antibody market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global CD62L Antibody market size and forecasts, in consumption value ($ Million), 2018-2029
  • Global CD62L Antibody market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
  • Global CD62L Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
  • Global CD62L Antibody market shares of main players, in revenue ($ Million), 2018-2023.

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for CD62L Antibody
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace.

This report profiles key players in the global CD62L Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Leinco Technologies, Bio-Rad, BD Biosciences and Proteintech Group, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

CD62L Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Monoclonal
  • Polyclonal

Market segment by Application

  • Immunochemistry (IHC)
  • Immunofluorescence (IF)
  • Immunoprecipitation (IP)
  • Western Blot (WB)
  • ELISA
  • Others

Market segment by players, this report covers

  • Thermo Fisher Scientific
  • Leinco Technologies
  • Bio-Rad
  • BD Biosciences
  • Proteintech Group
  • RayBiotech
  • Abcam
  • GeneTex
  • LifeSpan BioSciences
  • BioLegend
  • Antigenix America
  • NSJ Bioreagents
  • ichorbio
  • Miltenyi Biotec
  • Cell Sciences
  • Abbexa
  • Bio X Cell
  • Tonbo Biosciences
  • Biobyt
  • Jingjie PTM BioLab

Market segment by regions, regional analysis covers

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
  • South America (Brazil, Argentina and Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe CD62L Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CD62L Antibody, with revenue, gross margin and global market share of CD62L Antibody from 2018 to 2023.
Chapter 3, the CD62L Antibody competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and CD62L Antibody market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of CD62L Antibody.
Chapter 13, to describe CD62L Antibody research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of CD62L Antibody
1.2 Market Estimation Caveats and Base Year
1.3 Classification of CD62L Antibody by Type
1.3.1 Overview: Global CD62L Antibody Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global CD62L Antibody Consumption Value Market Share by Type in 2022
1.3.3 Monoclonal
1.3.4 Polyclonal
1.4 Global CD62L Antibody Market by Application
1.4.1 Overview: Global CD62L Antibody Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Immunochemistry (IHC)
1.4.3 Immunofluorescence (IF)
1.4.4 Immunoprecipitation (IP)
1.4.5 Western Blot (WB)
1.4.6 ELISA
1.4.7 Others
1.5 Global CD62L Antibody Market Size & Forecast
1.6 Global CD62L Antibody Market Size and Forecast by Region
1.6.1 Global CD62L Antibody Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global CD62L Antibody Market Size by Region, (2018-2029)
1.6.3 North America CD62L Antibody Market Size and Prospect (2018-2029)
1.6.4 Europe CD62L Antibody Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific CD62L Antibody Market Size and Prospect (2018-2029)
1.6.6 South America CD62L Antibody Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa CD62L Antibody Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Thermo Fisher Scientific
2.1.1 Thermo Fisher Scientific Details
2.1.2 Thermo Fisher Scientific Major Business
2.1.3 Thermo Fisher Scientific CD62L Antibody Product and Solutions
2.1.4 Thermo Fisher Scientific CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.2 Leinco Technologies
2.2.1 Leinco Technologies Details
2.2.2 Leinco Technologies Major Business
2.2.3 Leinco Technologies CD62L Antibody Product and Solutions
2.2.4 Leinco Technologies CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Leinco Technologies Recent Developments and Future Plans
2.3 Bio-Rad
2.3.1 Bio-Rad Details
2.3.2 Bio-Rad Major Business
2.3.3 Bio-Rad CD62L Antibody Product and Solutions
2.3.4 Bio-Rad CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Bio-Rad Recent Developments and Future Plans
2.4 BD Biosciences
2.4.1 BD Biosciences Details
2.4.2 BD Biosciences Major Business
2.4.3 BD Biosciences CD62L Antibody Product and Solutions
2.4.4 BD Biosciences CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 BD Biosciences Recent Developments and Future Plans
2.5 Proteintech Group
2.5.1 Proteintech Group Details
2.5.2 Proteintech Group Major Business
2.5.3 Proteintech Group CD62L Antibody Product and Solutions
2.5.4 Proteintech Group CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Proteintech Group Recent Developments and Future Plans
2.6 RayBiotech
2.6.1 RayBiotech Details
2.6.2 RayBiotech Major Business
2.6.3 RayBiotech CD62L Antibody Product and Solutions
2.6.4 RayBiotech CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 RayBiotech Recent Developments and Future Plans
2.7 Abcam
2.7.1 Abcam Details
2.7.2 Abcam Major Business
2.7.3 Abcam CD62L Antibody Product and Solutions
2.7.4 Abcam CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Abcam Recent Developments and Future Plans
2.8 GeneTex
2.8.1 GeneTex Details
2.8.2 GeneTex Major Business
2.8.3 GeneTex CD62L Antibody Product and Solutions
2.8.4 GeneTex CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GeneTex Recent Developments and Future Plans
2.9 LifeSpan BioSciences
2.9.1 LifeSpan BioSciences Details
2.9.2 LifeSpan BioSciences Major Business
2.9.3 LifeSpan BioSciences CD62L Antibody Product and Solutions
2.9.4 LifeSpan BioSciences CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 LifeSpan BioSciences Recent Developments and Future Plans
2.10 BioLegend
2.10.1 BioLegend Details
2.10.2 BioLegend Major Business
2.10.3 BioLegend CD62L Antibody Product and Solutions
2.10.4 BioLegend CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 BioLegend Recent Developments and Future Plans
2.11 Antigenix America
2.11.1 Antigenix America Details
2.11.2 Antigenix America Major Business
2.11.3 Antigenix America CD62L Antibody Product and Solutions
2.11.4 Antigenix America CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Antigenix America Recent Developments and Future Plans
2.12 NSJ Bioreagents
2.12.1 NSJ Bioreagents Details
2.12.2 NSJ Bioreagents Major Business
2.12.3 NSJ Bioreagents CD62L Antibody Product and Solutions
2.12.4 NSJ Bioreagents CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 NSJ Bioreagents Recent Developments and Future Plans
2.13 ichorbio
2.13.1 ichorbio Details
2.13.2 ichorbio Major Business
2.13.3 ichorbio CD62L Antibody Product and Solutions
2.13.4 ichorbio CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 ichorbio Recent Developments and Future Plans
2.14 Miltenyi Biotec
2.14.1 Miltenyi Biotec Details
2.14.2 Miltenyi Biotec Major Business
2.14.3 Miltenyi Biotec CD62L Antibody Product and Solutions
2.14.4 Miltenyi Biotec CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Miltenyi Biotec Recent Developments and Future Plans
2.15 Cell Sciences
2.15.1 Cell Sciences Details
2.15.2 Cell Sciences Major Business
2.15.3 Cell Sciences CD62L Antibody Product and Solutions
2.15.4 Cell Sciences CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Cell Sciences Recent Developments and Future Plans
2.16 Abbexa
2.16.1 Abbexa Details
2.16.2 Abbexa Major Business
2.16.3 Abbexa CD62L Antibody Product and Solutions
2.16.4 Abbexa CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Abbexa Recent Developments and Future Plans
2.17 Bio X Cell
2.17.1 Bio X Cell Details
2.17.2 Bio X Cell Major Business
2.17.3 Bio X Cell CD62L Antibody Product and Solutions
2.17.4 Bio X Cell CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Bio X Cell Recent Developments and Future Plans
2.18 Tonbo Biosciences
2.18.1 Tonbo Biosciences Details
2.18.2 Tonbo Biosciences Major Business
2.18.3 Tonbo Biosciences CD62L Antibody Product and Solutions
2.18.4 Tonbo Biosciences CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Tonbo Biosciences Recent Developments and Future Plans
2.19 Biobyt
2.19.1 Biobyt Details
2.19.2 Biobyt Major Business
2.19.3 Biobyt CD62L Antibody Product and Solutions
2.19.4 Biobyt CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Biobyt Recent Developments and Future Plans
2.20 Jingjie PTM BioLab
2.20.1 Jingjie PTM BioLab Details
2.20.2 Jingjie PTM BioLab Major Business
2.20.3 Jingjie PTM BioLab CD62L Antibody Product and Solutions
2.20.4 Jingjie PTM BioLab CD62L Antibody Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Jingjie PTM BioLab Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global CD62L Antibody Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of CD62L Antibody by Company Revenue
3.2.2 Top 3 CD62L Antibody Players Market Share in 2022
3.2.3 Top 6 CD62L Antibody Players Market Share in 2022
3.3 CD62L Antibody Market: Overall Company Footprint Analysis
3.3.1 CD62L Antibody Market: Region Footprint
3.3.2 CD62L Antibody Market: Company Product Type Footprint
3.3.3 CD62L Antibody Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global CD62L Antibody Consumption Value and Market Share by Type (2018-2023)
4.2 Global CD62L Antibody Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global CD62L Antibody Consumption Value Market Share by Application (2018-2023)
5.2 Global CD62L Antibody Market Forecast by Application (2024-2029)
6 North America
6.1 North America CD62L Antibody Consumption Value by Type (2018-2029)
6.2 North America CD62L Antibody Consumption Value by Application (2018-2029)
6.3 North America CD62L Antibody Market Size by Country
6.3.1 North America CD62L Antibody Consumption Value by Country (2018-2029)
6.3.2 United States CD62L Antibody Market Size and Forecast (2018-2029)
6.3.3 Canada CD62L Antibody Market Size and Forecast (2018-2029)
6.3.4 Mexico CD62L Antibody Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe CD62L Antibody Consumption Value by Type (2018-2029)
7.2 Europe CD62L Antibody Consumption Value by Application (2018-2029)
7.3 Europe CD62L Antibody Market Size by Country
7.3.1 Europe CD62L Antibody Consumption Value by Country (2018-2029)
7.3.2 Germany CD62L Antibody Market Size and Forecast (2018-2029)
7.3.3 France CD62L Antibody Market Size and Forecast (2018-2029)
7.3.4 United Kingdom CD62L Antibody Market Size and Forecast (2018-2029)
7.3.5 Russia CD62L Antibody Market Size and Forecast (2018-2029)
7.3.6 Italy CD62L Antibody Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific CD62L Antibody Consumption Value by Type (2018-2029)
8.2 Asia-Pacific CD62L Antibody Consumption Value by Application (2018-2029)
8.3 Asia-Pacific CD62L Antibody Market Size by Region
8.3.1 Asia-Pacific CD62L Antibody Consumption Value by Region (2018-2029)
8.3.2 China CD62L Antibody Market Size and Forecast (2018-2029)
8.3.3 Japan CD62L Antibody Market Size and Forecast (2018-2029)
8.3.4 South Korea CD62L Antibody Market Size and Forecast (2018-2029)
8.3.5 India CD62L Antibody Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia CD62L Antibody Market Size and Forecast (2018-2029)
8.3.7 Australia CD62L Antibody Market Size and Forecast (2018-2029)
9 South America
9.1 South America CD62L Antibody Consumption Value by Type (2018-2029)
9.2 South America CD62L Antibody Consumption Value by Application (2018-2029)
9.3 South America CD62L Antibody Market Size by Country
9.3.1 South America CD62L Antibody Consumption Value by Country (2018-2029)
9.3.2 Brazil CD62L Antibody Market Size and Forecast (2018-2029)
9.3.3 Argentina CD62L Antibody Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa CD62L Antibody Consumption Value by Type (2018-2029)
10.2 Middle East & Africa CD62L Antibody Consumption Value by Application (2018-2029)
10.3 Middle East & Africa CD62L Antibody Market Size by Country
10.3.1 Middle East & Africa CD62L Antibody Consumption Value by Country (2018-2029)
10.3.2 Turkey CD62L Antibody Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia CD62L Antibody Market Size and Forecast (2018-2029)
10.3.4 UAE CD62L Antibody Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 CD62L Antibody Market Drivers
11.2 CD62L Antibody Market Restraints
11.3 CD62L Antibody Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 CD62L Antibody Industry Chain
12.2 CD62L Antibody Upstream Analysis
12.3 CD62L Antibody Midstream Analysis
12.4 CD62L Antibody Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock